Patents by Inventor Jeffrey S. Rubin
Jeffrey S. Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938185Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.Type: GrantFiled: December 15, 2020Date of Patent: March 26, 2024Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 8735355Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: GrantFiled: March 21, 2012Date of Patent: May 27, 2014Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of MassachusettsInventors: Jeffrey S. Rubin, Susan Cumberledge, Frieda Reichsman, Aykut Uren
-
Patent number: 8334260Abstract: This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also includes methods of regulating the interaction of sFRP-1 with proteins containing the motif.Type: GrantFiled: January 24, 2008Date of Patent: December 18, 2012Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, St. Vincent's Institute of Medical ResearchInventors: Jeffrey S. Rubin, Aykut Üren, Brian K. Kay, Bernard Weisblum, Matthew Todd Gillespie, Nicole Joy Horwood
-
Publication number: 20120202749Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: ApplicationFiled: March 21, 2012Publication date: August 9, 2012Inventors: Jeffrey S. Rubin, Susan Cumberledge, Frieda Reichsman, Aykut Uren
-
Patent number: 8158603Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: GrantFiled: February 18, 2011Date of Patent: April 17, 2012Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of MassachusettsInventors: Jeffrey S. Rubin, Aykut Üren, Susan Cumberledge, Frieda Reichsman
-
Publication number: 20110177554Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: ApplicationFiled: February 18, 2011Publication date: July 21, 2011Applicants: The Gov. of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services, The University of MassachusettsInventors: JEFFREY S. RUBIN, SUSAN CUMBERLEDGE, FRIEDA REICHSMAN, AYKUT UREN
-
Patent number: 7947651Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: GrantFiled: May 15, 2007Date of Patent: May 24, 2011Assignees: The United States of America as represented by the Department of Health and Human Services, University of MassachusettsInventors: Jeffrey S. Rubin, Susan Cumberledge, Frieda Reichsman, Aykut Uren
-
Patent number: 7605127Abstract: The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purification, molecular cloning, recombinant expression of the truncated HGF variants and related pharmaceutical compositions. The present invention further relates to the utilization of the small HGF variants to either inhibit HGF mitogenesis or stimulate HGF mitogenesis in cells expressing the receptor for HGF.Type: GrantFiled: October 30, 2002Date of Patent: October 20, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Andrew M. L. Chan, Jeffrey S. Rubin, Donald P. Bottaro, Stuart A. Aaronson, Stephen J. Stahl, Paul T. Wingfield, Vittoria Cioce
-
Patent number: 7488710Abstract: This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also includes methods of regulating the interaction of sFRP-1 with proteins containing the motif.Type: GrantFiled: January 10, 2002Date of Patent: February 10, 2009Assignees: The United States of America as represented by the Department of Health and Human Services, St. Vincent's Institute of Medical ResearchInventors: Jeffrey S. Rubin, Aykut Üren, Matthew Todd Gillespie, Nicole Joy Horwood
-
Publication number: 20080207504Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: ApplicationFiled: May 15, 2007Publication date: August 28, 2008Inventors: Jeffrey S. Rubin, Susan Cumberledge, Frieda Reichsman, Aykut Uren
-
Publication number: 20080145884Abstract: This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also includes methods of regulating the interaction of sFRP-1 with proteins containing the motif.Type: ApplicationFiled: January 24, 2008Publication date: June 19, 2008Inventors: Jeffrey S. Rubin, Aykut Oren, Brian K. Kay, Bernard Weisblum, Matthew Tood Gillespie, Nicole Joy Horwood
-
Patent number: 7223853Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: GrantFiled: April 28, 2003Date of Patent: May 29, 2007Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services., The University of MassachusettsInventors: Frieda Reichsman, Aykut Üren, Jeffrey S. Rubin, Susan Cumberledge
-
Patent number: 7183377Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.Type: GrantFiled: May 3, 2002Date of Patent: February 27, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey S. Rubin, Paul Finch, Stuart Aaronson, Xi He
-
Patent number: 7026291Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.Type: GrantFiled: June 7, 1995Date of Patent: April 11, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey S. Rubin, Paul W. Finch, Stuart A. Aaronson
-
Patent number: 6833132Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.Type: GrantFiled: May 31, 1995Date of Patent: December 21, 2004Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jeffrey S. Rubin, Paul W. Finch, Stuart A. Aaronson
-
Publication number: 20040077828Abstract: This disclosure relates to a peptide motif and proteins containing the motif that are capable of binding to secreted Frizzled-related protein family members. Accordingly, the disclosure also includes methods of regulating the interaction of sFRP-1 with proteins containing the motif.Type: ApplicationFiled: July 10, 2003Publication date: April 22, 2004Inventors: Jeffrey S. Rubin, Aykut Uren, Brian K. Kay, Bernard Weisblum, Matthew Todd Gillespie, Nicole Joy Horwood
-
Patent number: 6709842Abstract: Disccoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.Type: GrantFiled: June 7, 1995Date of Patent: March 23, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey S. Rubin, Paul W. Finch, Stuart A. Aaronson
-
Publication number: 20030187223Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: ApplicationFiled: April 28, 2003Publication date: October 2, 2003Applicants: The Government of the United States of America as represented by the, Secretary of the Department of Health and Human Services, The University of MassachusettsInventors: Frieda Reichsman, Aykut Uren, Jeffrey S. Rubin, Susan Cumberledge
-
Publication number: 20030175864Abstract: The invention provides a novel, secreted protein that contains a region homologous to ligand binding domain of a cytokine receptor. This protein, called Frizzled-related protein (FRP), antagonizes the signaling of the Wnt family of cytokines. Extracellular signaling molecules such as the Wnt family members have essential roles as inducers of cellular proliferation, migration, differentiation, and tissue morphogenesis. As Wnt molecules are known to participate in the aberrant growth associated with neoplasia, Wnt antagonists such as FRP are valuable tools which both for understanding oncogenesis and for the design of new cancer therapies.Type: ApplicationFiled: May 3, 2002Publication date: September 18, 2003Applicant: Secretary, Department of Health and Human ServicesInventors: Jeffrey S. Rubin, Paul Finch, Stuart Aaronson, Xi He
-
Patent number: 6600018Abstract: The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of sFRP that do not contain the CRD domain are shown to bind to Wnt proteins and modulate Wnt biological activity. Accordingly, the invention provides these sFRP fragments and variants of these fragments, as well as vectors and host cells containing nucleic acid sequences encoding the sFRP fragments and variants.Type: GrantFiled: April 10, 2000Date of Patent: July 29, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey S. Rubin, Susan Cumberledge, Frieda Reichsman, Aykut Uren